Finnish medical device company Bioretec Ltd. announced on Friday that it has received CE mark approval for its RemeOs Trauma Screw product portfolio, enabling commercialization in the European Union and other CE mark-recognizing markets.
Approval covers all cannulated and non-cannulated designs, including RemeOs FT, RemeOs FL, RemeOs FC, and RemeOs LAG Solid, with diameters from 2.0mm to 4.0mm and lengths from 8mm to 50mm. Indications include fracture and malalignment fixations in adult and pediatric patients, excluding the hand and forefoot.
EU market approval allows Bioretec Ltd. to immediately introduce the full RemeOs Trauma Screw portfolio across Europe. Expansion into non-European CE mark-recognizing markets is now possible, alongside real-world clinical data collection. Insights gained may support broader US regulatory approvals.
Bioretec Ltd secures CE mark approval for RemeOs Trauma Screw portfolio
Biohit launches FAEX Sample System for stool sample collection
Renalys Pharma completes patient enrolment for Phase III clinical trial of sparsentan
Innocan Pharma's BI Sky Global completes industry standard safety test
ColdVentures partners with Medco Sports Medicine to combat heat stroke
Median Technologies secures funding for eyonis Lung Cancer Screening software
MicroAire Surgical Instruments acquires NEOSYAD
UCB launches 320 mg/2 mL single-injection administration option for BIMZELX (bimekizumab-bkzx) in US
Concept Medical reports first patient enrolled in MagicTouch SCB trial in peripheral artery disease
Creo Medical Group plc launches robotic-guided lung ablation procedures in the UK